Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Year: 2015
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Journal of Clinical Oncology
Authors: Robert H.I. Andtbacka, Howard L. Kaufman, Frances Collichio, Thomas Amatruda, Neil Senzer, Jason Chesney, Keith A. Delman, Lynn E. Spitler, Igor Puzanov, Sanjiv S. Agarwala, Mohammed Milhem, Lee Cranmer, Brendan Curti, Karl Lewis, Merrick Ross, Troy Guthrie, Gerald P. Linette, Gregory A. Daniels, Kevin Harrington, Mark R. Middleton, Wilson H. Miller, Jonathan S. Zager, Yining Ye, Bin Yao, Ai Li, Susan Doleman, Ari VanderWalde, Jennifer Gansert, Robert S. Coffin
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: Amgen, Rosetrees Trust
Award: G516334265
OpenAlex ID: W2109274792